Mark M Cullen, Warren Floyd, Bobby Dow, Beatrice Schleupner, Brian E Brigman, Julia D Visgauss, Diana M Cardona, Jason A Somarelli, William C Eward
{"title":"ATRX 及其在软组织肉瘤中的预后意义","authors":"Mark M Cullen, Warren Floyd, Bobby Dow, Beatrice Schleupner, Brian E Brigman, Julia D Visgauss, Diana M Cardona, Jason A Somarelli, William C Eward","doi":"10.1155/2024/4001796","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Recently, the association between ATRX and a more aggressive sarcoma phenotype has been shown. We performed a retrospective study of sarcomas from an individual institution to evaluate ATRX as a prognosticator in soft tissue sarcoma. <i>Experimental Design</i>. 128 sarcomas were collected from a single institution and stained for ATRX. The prognostic significance of these markers was evaluated in a smaller cohort of primary soft tissue sarcomas (<i>n</i> = 68). Kaplan-Meier curves were created for univariate analysis, and Cox regression was utilized for multivariate analysis.</p><p><strong>Results: </strong>High expression of ATRX was found to be a positive prognostic indicator for overall survival and metastasis-free survival in our group of soft tissue sarcomas both in univariate analysis and multivariate analysis (HR: 0.38 (0.17-0.85), <i>P</i>=0.02 and HR: 0.49 (0.24-0.99), <i>P</i>=0.05, respectively).</p><p><strong>Conclusions: </strong>High expression of ATRX is a positive prognostic indicator of overall survival and metastasis-free survival in patients with STS. This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.</p>","PeriodicalId":21431,"journal":{"name":"Sarcoma","volume":"2024 ","pages":"4001796"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090676/pdf/","citationCount":"0","resultStr":"{\"title\":\"ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.\",\"authors\":\"Mark M Cullen, Warren Floyd, Bobby Dow, Beatrice Schleupner, Brian E Brigman, Julia D Visgauss, Diana M Cardona, Jason A Somarelli, William C Eward\",\"doi\":\"10.1155/2024/4001796\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Recently, the association between ATRX and a more aggressive sarcoma phenotype has been shown. We performed a retrospective study of sarcomas from an individual institution to evaluate ATRX as a prognosticator in soft tissue sarcoma. <i>Experimental Design</i>. 128 sarcomas were collected from a single institution and stained for ATRX. The prognostic significance of these markers was evaluated in a smaller cohort of primary soft tissue sarcomas (<i>n</i> = 68). Kaplan-Meier curves were created for univariate analysis, and Cox regression was utilized for multivariate analysis.</p><p><strong>Results: </strong>High expression of ATRX was found to be a positive prognostic indicator for overall survival and metastasis-free survival in our group of soft tissue sarcomas both in univariate analysis and multivariate analysis (HR: 0.38 (0.17-0.85), <i>P</i>=0.02 and HR: 0.49 (0.24-0.99), <i>P</i>=0.05, respectively).</p><p><strong>Conclusions: </strong>High expression of ATRX is a positive prognostic indicator of overall survival and metastasis-free survival in patients with STS. This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.</p>\",\"PeriodicalId\":21431,\"journal\":{\"name\":\"Sarcoma\",\"volume\":\"2024 \",\"pages\":\"4001796\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11090676/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sarcoma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2024/4001796\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/4001796","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.
Purpose: Recently, the association between ATRX and a more aggressive sarcoma phenotype has been shown. We performed a retrospective study of sarcomas from an individual institution to evaluate ATRX as a prognosticator in soft tissue sarcoma. Experimental Design. 128 sarcomas were collected from a single institution and stained for ATRX. The prognostic significance of these markers was evaluated in a smaller cohort of primary soft tissue sarcomas (n = 68). Kaplan-Meier curves were created for univariate analysis, and Cox regression was utilized for multivariate analysis.
Results: High expression of ATRX was found to be a positive prognostic indicator for overall survival and metastasis-free survival in our group of soft tissue sarcomas both in univariate analysis and multivariate analysis (HR: 0.38 (0.17-0.85), P=0.02 and HR: 0.49 (0.24-0.99), P=0.05, respectively).
Conclusions: High expression of ATRX is a positive prognostic indicator of overall survival and metastasis-free survival in patients with STS. This is consistent with studies in osteosarcoma, which indicate possible mechanisms through which loss of ATRX leads to more aggressive phenotypes. Future prospective clinical studies are required to validate the prognostic significance of these findings.
SarcomaMedicine-Radiology, Nuclear Medicine and Imaging
CiteScore
5.00
自引率
0.00%
发文量
15
审稿时长
14 weeks
期刊介绍:
Sarcoma is dedicated to publishing papers covering all aspects of connective tissue oncology research. It brings together work from scientists and clinicians carrying out a broad range of research in this field, including the basic sciences, molecular biology and pathology and the clinical sciences of epidemiology, surgery, radiotherapy and chemotherapy. High-quality papers concerning the entire range of bone and soft tissue sarcomas in both adults and children, including Kaposi"s sarcoma, are published as well as preclinical and animal studies. This journal provides a central forum for the description of advances in diagnosis, assessment and treatment of this rarely seen, but often mismanaged, group of patients.